Showing 4231-4240 of 5996 results for "".
- With New Roles for Company Vets, Crown Doubles Down on Commitment to Aestheticshttps://practicaldermatology.com/news/with-new-roles-for-industry-vets-crown-doubles-down-on-commitment-to-aesthetics/2461242/Joe Proctor and Michael McKenna are stepping into new roles at Crown Laboratories. Joe Proctor will transition from General Manager, Aesthetics into the Head of Innovation and Corporate Development for Crown Aesthetics. Mr. Proctor is the founder of Crown
- Dermatologists Rule for Cosmetic Procedures and Skin Care Decisionshttps://practicaldermatology.com/news/dermatologists-rule-for-cosmetic-procedures-and-skin-care-decisions/2461241/Dermatologists rank as the number one influencer among 16 factors that impact consumers’ decisions to have a cosmetic procedure, according to the 2021
- New Crystal Ball Predictions Released by Allergan Aestheticshttps://practicaldermatology.com/news/new-crystal-ball-predictions-released-by-allergan-aesthetics/2461238/Consumer interest in medical aesthetics continues to rise, with the number of dermal filler treatments worldwide growing by almost two million between 2017 and 2020, according to Allergan Aesthetics’ 'The Future of Aesthetics' global trends report. In addition, the r
- Happify Health, Almirall Go Live with Digital Solution to Support Psoriasis Patientshttps://practicaldermatology.com/news/happify-health-almirall-go-live-with-digital-solution-to-support-psoriasis-patients/2461234/Happify Health and Almirall S.A.’s new digital platform Claro is live and now available to people with psoriasis in Spain, Italy and the United Kingdom. Claro was built to improve the mental well-being of people with psoriasis through cognitive behavioral therapy, positive psychology, and m
- Higher Fish Consumption Linked to Melanoma Riskhttps://practicaldermatology.com/news/higher-fish-consumption-linked-to-melanoma-risk/2461229/Eating higher levels of fish, including tuna and non-fried fish, may increase melanoma risk, according to a large study of US adults published in Cancer Causes & Control. When compared to those whose median daily fish intake was 3.2 grams, the risk of malignant melanom
- New Research Reveals Roughly 4 in 5 Acne Sufferers Have Missed Moments in Their Life Due to Acnehttps://practicaldermatology.com/news/new-research-reveals-roughly-4-in-5-acne-sufferers-have-missed-moments-in-their-life-due-to-acne/2461227/Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc., which offers AviClear, the first
- And the Winners Are...Newsweek Names America’s Top Dermatologistshttps://practicaldermatology.com/news/and-the-winners-arenewsweek-names-americas-top-dermatologists/2461226/Newsweek has released the 2022 America‘s Best Dermatologists List in partnership with Statista. The list is split into two categories: cosmetic and medical and includes 275 dermatologists (125 cosmetic and 150 medical), many of whom sit on Practical Dermatology® and sister pub
- FDA Approves Dupixent for Children 6 Months to 5 Years with Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis/2461224/The FDA has approved Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab) for children aged 6 months to 5 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regu
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- June 2022 Marks Scleroderma Awareness Monthhttps://practicaldermatology.com/news/june-2022-marks-scleroderma-awareness-month/2461222/June is Scleroderma Awareness Month, and "Know Scleroderma" is the National Scleroderma Foundation's theme for 2022. Throughout the month, the Foundation will post videos and photos of individuals affected by scleroderma on its